Within the PD-(L)1 class, Keytruda is responsible for over 55% of the total global sales. Its current revenue total makes ...

Keytruda is currently indicated in a variety of cancers, including classical Hodgkin lymphoma, primary mediastinal large ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... The main difference is BNT327 targets PD-L1 while ivonescimab ...

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is ...